Abbott Laboratories ABT
- Market cap
- $174.8B
- P/E
- 32.8×
Follow ABT
Abbott Laboratories (ABT) EV/Sales
As of 25 September 2026, Abbott Laboratories (ABT) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from 2.6× (September 2015) to 6.9× (February 2021); the current reading is higher than 34% of that period. That is above the Medical Devices industry median of 2.4× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.0× | 3.56% |
| FY2024 | 4.8× | (2.25%) |
| FY2023 | 5.0× | 8.75% |
| FY2022 | 4.6× | (23.89%) |
| FY2021 | 6.0× | 0.71% |
| FY2020 | 5.9× | 13.20% |
| FY2019 | 5.2× | 12.62% |
| FY2018 | 4.7× | 5.96% |
| FY2017 | 4.4× | 53.84% |
| FY2016 | 2.9× | (12.89%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.0× | (12.88%) |
| Mar 2026 | 4.6× | (9.07%) |
| Dec 2025 | 5.0× | (7.91%) |
| Sep 2025 | 5.4× | (3.59%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.9× |
| MDT Medtronic PLC compare | 3.5× |
| STE STERIS plc compare | 3.6× |
| BSX Boston Scientific Corporation compare | 3.7× |
| ABT Abbott Laboratories | 4.4× |
| SYK Stryker Corporation compare | 4.5× |
| DXCM DexCom, Inc. compare | 6.5× |
| EW Edwards Lifesciences Corporation compare | 7.1× |
| Medical Devices industry median | 2.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on ABT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement